FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3140107493> ?p ?o ?g. }

• W3140107493 endingPage "481" @default.
• W3140107493 startingPage "474" @default.
• W3140107493 abstract "Background The only established treatment for preventing colorectal cancer in patients with familial adenomatous polyposis (FAP) is colectomy, which greatly reduces patient quality of life. Thus, an alternative method is warranted. In this trial, we aimed to clarify the individual and joint effects of low-dose aspirin and mesalazine on the recurrence of colorectal polyps in Japanese patients with FAP. Methods This was a randomised, double-blind, placebo-controlled, multicentre trial with a two-by-two factorial design done in 11 centres in Japan. Eligible patients were aged 16–70 years and had a history of more than 100 adenomatous polyps in the large intestine, without a history of colectomy. Before the study, patients underwent endoscopic removal of all colorectal polyps of at least 5·0 mm in diameter. Randomisation was done with a minimisation method with a random component to balance the groups with respect to the adjustment factors of sex, age (<30 years vs ≥30 years), or smoking status at the time of entry. Patients and researchers were masked to the treatment group. There were four groups: aspirin (100 mg per day) plus mesalazine (2 g per day), aspirin (100 mg per day) plus mesalazine placebo, aspirin placebo plus mesalazine (2 g per day), or aspirin placebo plus mesalazine placebo. Treatment was continued until 1 week before 8 month colonoscopy. The primary endpoint was the incidence of colorectal polyps of at least 5·0 mm at 8 months and was assessed in the intention-to-treat population. Safety was assessed in the ITT population. We also did a per-protocol analysis including only patients who took at least 70% of the allocated study drug. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000018736, and is complete. Findings Between Sept 25, 2015, and March 13, 2017, 104 patients were randomly assigned to receive either aspirin or aspirin placebo (n=52) or mesalazine or mesalazine placebo (n=52). Two patients withdrew from the aspirin plus mesalazine placebo group. 26 (50%) of 52 patients who received no aspirin had colorectal polyps of at least 5·0 mm at 8 months, as did 15 (30%) of the 50 patients who received any aspirin, 21 (42%) of the 50 patients who received no mesalazine, and 20 (38%) of the 52 patients who received any mesalazine. The adjusted odds ratio for polyp recurrence was 0·37 (95% CI 0·16–0·86) in the patients who received any aspirin and 0·87 (95% CI 0·38–2·00) in any who received mesalazine. The most common adverse events were grade 1–2 upper gastrointestinal symptoms in three (12%) of 26 patients who received aspirin plus mesalazine, one (4%) of 24 patients who received aspirin plus mesalazine placebo, and one (4%) of 26 patients who received mesalazine plus aspirin placebo. There was one grade 4 event in the mesalazine plus aspirin placebo group, but not related to the treatment. Interpretation Low-dose aspirin safely suppressed the recurrence of colorectal polyps larger than 5·0 mm in patients with FAP. These results suggest an effect of low-dose aspirin for FAP and could be an alternative method for preventing colorectal cancer in FAP. Funding Japan Agency for Medical Research and Development. The only established treatment for preventing colorectal cancer in patients with familial adenomatous polyposis (FAP) is colectomy, which greatly reduces patient quality of life. Thus, an alternative method is warranted. In this trial, we aimed to clarify the individual and joint effects of low-dose aspirin and mesalazine on the recurrence of colorectal polyps in Japanese patients with FAP. This was a randomised, double-blind, placebo-controlled, multicentre trial with a two-by-two factorial design done in 11 centres in Japan. Eligible patients were aged 16–70 years and had a history of more than 100 adenomatous polyps in the large intestine, without a history of colectomy. Before the study, patients underwent endoscopic removal of all colorectal polyps of at least 5·0 mm in diameter. Randomisation was done with a minimisation method with a random component to balance the groups with respect to the adjustment factors of sex, age (<30 years vs ≥30 years), or smoking status at the time of entry. Patients and researchers were masked to the treatment group. There were four groups: aspirin (100 mg per day) plus mesalazine (2 g per day), aspirin (100 mg per day) plus mesalazine placebo, aspirin placebo plus mesalazine (2 g per day), or aspirin placebo plus mesalazine placebo. Treatment was continued until 1 week before 8 month colonoscopy. The primary endpoint was the incidence of colorectal polyps of at least 5·0 mm at 8 months and was assessed in the intention-to-treat population. Safety was assessed in the ITT population. We also did a per-protocol analysis including only patients who took at least 70% of the allocated study drug. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000018736, and is complete. Between Sept 25, 2015, and March 13, 2017, 104 patients were randomly assigned to receive either aspirin or aspirin placebo (n=52) or mesalazine or mesalazine placebo (n=52). Two patients withdrew from the aspirin plus mesalazine placebo group. 26 (50%) of 52 patients who received no aspirin had colorectal polyps of at least 5·0 mm at 8 months, as did 15 (30%) of the 50 patients who received any aspirin, 21 (42%) of the 50 patients who received no mesalazine, and 20 (38%) of the 52 patients who received any mesalazine. The adjusted odds ratio for polyp recurrence was 0·37 (95% CI 0·16–0·86) in the patients who received any aspirin and 0·87 (95% CI 0·38–2·00) in any who received mesalazine. The most common adverse events were grade 1–2 upper gastrointestinal symptoms in three (12%) of 26 patients who received aspirin plus mesalazine, one (4%) of 24 patients who received aspirin plus mesalazine placebo, and one (4%) of 26 patients who received mesalazine plus aspirin placebo. There was one grade 4 event in the mesalazine plus aspirin placebo group, but not related to the treatment. Low-dose aspirin safely suppressed the recurrence of colorectal polyps larger than 5·0 mm in patients with FAP. These results suggest an effect of low-dose aspirin for FAP and could be an alternative method for preventing colorectal cancer in FAP." @default.
• W3140107493 created "2021-04-13" @default.
• W3140107493 creator A5000409879 @default.
• W3140107493 creator A5005877279 @default.
• W3140107493 creator A5012400291 @default.
• W3140107493 creator A5013263645 @default.
• W3140107493 creator A5015262464 @default.
• W3140107493 creator A5016091427 @default.
• W3140107493 creator A5019497011 @default.
• W3140107493 creator A5021158752 @default.
• W3140107493 creator A5025349821 @default.
• W3140107493 creator A5029053797 @default.
• W3140107493 creator A5030298726 @default.
• W3140107493 creator A5032476651 @default.
• W3140107493 creator A5034108220 @default.
• W3140107493 creator A5047284878 @default.
• W3140107493 creator A5052803318 @default.
• W3140107493 creator A5058445735 @default.
• W3140107493 creator A5067370791 @default.
• W3140107493 creator A5071345881 @default.
• W3140107493 creator A5073333764 @default.
• W3140107493 creator A5086850753 @default.
• W3140107493 creator A5090906332 @default.
• W3140107493 date "2021-06-01" @default.
• W3140107493 modified "2023-10-01" @default.
• W3140107493 title "Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial" @default.
• W3140107493 cites W1975076018 @default.
• W3140107493 cites W1993236167 @default.
• W3140107493 cites W2065861460 @default.
• W3140107493 cites W2076647438 @default.
• W3140107493 cites W2089094115 @default.
• W3140107493 cites W2097903769 @default.
• W3140107493 cites W2099108518 @default.
• W3140107493 cites W2102937816 @default.
• W3140107493 cites W2107534719 @default.
• W3140107493 cites W2114672214 @default.
• W3140107493 cites W2120453571 @default.
• W3140107493 cites W2125795237 @default.
• W3140107493 cites W2143590679 @default.
• W3140107493 cites W2148012410 @default.
• W3140107493 cites W2158131645 @default.
• W3140107493 cites W2158718772 @default.
• W3140107493 cites W2158968701 @default.
• W3140107493 cites W2304625472 @default.
• W3140107493 cites W2336169581 @default.
• W3140107493 cites W2789271913 @default.
• W3140107493 cites W2884727639 @default.
• W3140107493 cites W2944053573 @default.
• W3140107493 cites W3084327256 @default.
• W3140107493 doi "https://doi.org/10.1016/s2468-1253(21)00018-2" @default.
• W3140107493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33812492" @default.
• W3140107493 hasPublicationYear "2021" @default.
• W3140107493 type Work @default.
• W3140107493 sameAs 3140107493 @default.
• W3140107493 citedByCount "41" @default.
• W3140107493 countsByYear W31401074932021 @default.
• W3140107493 countsByYear W31401074932022 @default.
• W3140107493 countsByYear W31401074932023 @default.
• W3140107493 crossrefType "journal-article" @default.
• W3140107493 hasAuthorship W3140107493A5000409879 @default.
• W3140107493 hasAuthorship W3140107493A5005877279 @default.
• W3140107493 hasAuthorship W3140107493A5012400291 @default.
• W3140107493 hasAuthorship W3140107493A5013263645 @default.
• W3140107493 hasAuthorship W3140107493A5015262464 @default.
• W3140107493 hasAuthorship W3140107493A5016091427 @default.
• W3140107493 hasAuthorship W3140107493A5019497011 @default.
• W3140107493 hasAuthorship W3140107493A5021158752 @default.
• W3140107493 hasAuthorship W3140107493A5025349821 @default.
• W3140107493 hasAuthorship W3140107493A5029053797 @default.
• W3140107493 hasAuthorship W3140107493A5030298726 @default.
• W3140107493 hasAuthorship W3140107493A5032476651 @default.
• W3140107493 hasAuthorship W3140107493A5034108220 @default.
• W3140107493 hasAuthorship W3140107493A5047284878 @default.
• W3140107493 hasAuthorship W3140107493A5052803318 @default.
• W3140107493 hasAuthorship W3140107493A5058445735 @default.
• W3140107493 hasAuthorship W3140107493A5067370791 @default.
• W3140107493 hasAuthorship W3140107493A5071345881 @default.
• W3140107493 hasAuthorship W3140107493A5073333764 @default.
• W3140107493 hasAuthorship W3140107493A5086850753 @default.
• W3140107493 hasAuthorship W3140107493A5090906332 @default.
• W3140107493 hasConcept C105795698 @default.
• W3140107493 hasConcept C121608353 @default.
• W3140107493 hasConcept C126322002 @default.
• W3140107493 hasConcept C141071460 @default.
• W3140107493 hasConcept C168563851 @default.
• W3140107493 hasConcept C169222746 @default.
• W3140107493 hasConcept C2776667177 @default.
• W3140107493 hasConcept C2777628954 @default.
• W3140107493 hasConcept C2779134260 @default.
• W3140107493 hasConcept C2779174533 @default.
• W3140107493 hasConcept C2780479503 @default.
• W3140107493 hasConcept C2780814781 @default.
• W3140107493 hasConcept C33923547 @default.
• W3140107493 hasConcept C526805850 @default.
• W3140107493 hasConcept C71924100 @default.
• W3140107493 hasConcept C90924648 @default.
• W3140107493 hasConceptScore W3140107493C105795698 @default.
• W3140107493 hasConceptScore W3140107493C121608353 @default.

• next